Galapagos has inked a two-year, €3.3 million drug discovery deal with the University of Bristol in England. The partners will aim at developing treatments for diabetic neuropathic pain. Galapagos' service division BioFocus will provide hit-to-lead and lead optimization services for a Wellcome Trust funded program at the University of Bristol. Galapagos release